

**North of Tyne
Area Prescribing Committee**
www.northoftyneapc.nhs.uk

**Tuesday 14th May 2013.
Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt
Business Park.
The meeting will start at 12:30pm**

AGENDA

1. Apologies for absence
2. Declarations of interest
 - Relevant declarations
 - Annual declarations due.

Enclosure 2
3. Appeals against previous decisions
 - Plenadren MR
4. LDM Structures - QIPP Enc 4a and 4b
5. Minutes and decision summary from the meeting held on 12/3/13 Email 19/3/13
6. Matters arising/actions from previous meeting
 - Aflibercept – NETAG recommendation
7. Report from the Formulary sub-group
 - Draft minutes from meeting held on 22/4/13 Enclosed with agenda
 - Decision summary from meeting held on 22/4/13 Enclosed with agenda
 - Formulary version 4.3 updated on website
8. Report from the Shared Care Group
 - Draft minutes from 13/2/13 Enclosed with agenda
 - Traffic Light List 04/13 Updated on website Enclosed with agenda
 - Updated Melatonin Blue Information sheet Circulated for
 - Acetylcholinesterase leaflet. comment 24/4/13
9. Report from the Antimicrobial Chemotherapy Sub-group
 - No report due
10. Report from Medicines Management QIPP Sub-group
 - Draft minutes from 17/4/13 Enclosure 10

11. Annual report

Enclosure 11

12. Documents previously circulated by e-mail

- None

13. APC Guidelines and Statements for review

- [APC Guiding Principles on Prescribing Unlicensed Medicines – June 2009](#)
- [APC Guideline on Medicines that are Not Suitable for Generic Prescribing v1.1 – March 2012](#)
- [APC Statement on Clopidogrel and PPIs \(updated\) – July 2010](#)
- Denosumab Blue information sheet – updated with MHRA advice re atypical fractures.

Enclosed with agenda

14. NICE Technology Appraisals published in March and April

- TA276 - Cystic fibrosis (pseudomonas lung infection) - Colistimethate sodium and tobramycin.
- TA277 - Methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness receiving palliative care (terminated appraisal due to lack of submission)
- TA278 - Omalizumab for the treatment of severe persistent allergic asthma in children aged 6 and over and adults (review of TA133 and TA201).
- TA280 - Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234)
- TA281 -Gout - canakinumab (terminated appraisal) because no evidence submission was received from the manufacturer of the technology.
- TA282 - Pirfenidone for treating idiopathic pulmonary fibrosis.

15. Chairman's action

- Amendment of blood glucose testing document to include line relating to urine testing
- Amendment to "Comparison of New Oral Anticoagulants with Warfarin in AF – Information for Prescribers" document

Updated on website

Updated on website

16. Any other business

17. Date and time of next meeting:

Tuesday 9th July 2013

Room 3, Northumbria House, Unit 7/8 Silver Fox Way, Cobalt Business Park, North Tyneside.

The meeting will start at 12:30pm